ClinicalTrials.gg
TerminatedNCT05555615Updated Dec 3, 2025Results posted

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

A Phase 2/3 interventional study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder, sponsored by ACADIA Pharmaceuticals Inc.. Terminated at 48 sites in 8 countries. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by ACADIA Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment

Why this study was terminated
The study was terminated for business reasons and not due to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
209
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
64th of 658
209 · median 50
Started
2022
with 56 others
Phase 2/3
8 of 773
3 open now
Registered
566th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 64th largest by enrollment of the 658 interventional ones that give a count, is one of 57 that started in 2022, is one of 8 in phase 2/3, and was the 566th registered.

Autism Spectrum Disorder

1,729 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

160 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 300 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years).

ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).

Read the detailed description

This study will be conducted as a 52-week, open-label extension study of the antecedent double-blind study to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (5 through 17 years old at the time of enrolling into the antecedent double-blind study).

03

Conditions studied

  • Irritability Associated With Autism Spectrum Disorder
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has completed the treatment period of study ACP-103-069
  • prior to the conduct of any study procedures
  • Continues to be both clinically stable and not at imminent risk of suicide or injury to self, others, or property
  • Continues to be medically stable at enrollment
  • For female patients only: unable to become pregnant or agree to use a highly effective non-hormonal method of . Females of must have a negative pregnancy test

Exclusion criteria

EXCLUSION CRITERIA:

  • Patient or parent/legally accepted representative is judged by the Investigator to be inappropriate for the study
  • Requires treatment with a medication prohibited by the protocol, including concomitant psychotropic drugs targeting irritability, including those used off-label (clonidine, guanfacine, and propranolol; lithium, valproate), medications that prolong the ; and strong cytochrome P450 (CYP) 3A4 enzyme () inhibitors and inducers
  • At a significant risk of suicide, or is a danger to self or others
  • At risk of significant violent behavior to the extent that participation would pose an undue risk to other patients, caregivers, or others
  • Positive urine drug test
  • Serious and/or unstable psychiatric, neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or
  • Any change in medical or treatment status that may increase the risk associated with taking pimavanserin, would interfere with safety assessments, or would confound the interpretation of study results
  • abnormal of protocol-defined cardiac conduction abnormalities
  • Weight \<15 kg
  • Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    Pimavanserin

    Pimavanserin once daily. All patients will receive the pimavanserin low dose (patients aged 5 to 12 years: 10 mg/day pimavanserin; patients aged 13 to 17 years: 20 mg/day) the first 2 weeks of the study. Thereafter, the dose may be increased to the high dose (5 to 12 years: 20 mg/day; 13 to 17 years: 34 mg/day) based on the Investigator's assessment of clinical response. After Week 2 and up to Week 20, dose adjustments are allowed at any clinic visit based on the Investigator's assessment of clinical response and tolerability. No further dose adjustments are allowed after Week 20.

    Drug: Pimavanserin

Interventions

  • Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age

    Also known as: Nuplazid

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events

    Number (%) of patients with treatment emergent adverse events

    Time frame: 52 weeks

Secondary outcomes

  1. Aberrant Behavior Checklist-Irritability (ABC-I) and Clinical Global Impression-Improvement (CGI-I) Response Rate

    The response rate was defined as the proportion of patients with at least 25% reduction from baseline to Week 52 in ABC-I and a CGI-I of irritability score of 1 (very much improved) or 2 (much improved) at Week 52, compared to baseline. Baseline was the baseline of the antecedent double-blind study APC-103-069. The ABC is a parent/caregiver-rated scale comprised of 5 subscales encompassing 58 items. Subscales are irritability, lethargy, stereotypic behavior, hyperactivity, and inappropriate speech. Items are rated on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe), with higher scores indicating more severe problems. Subscale scores are calculated by summing the items within that subscale. The CGI-I is a clinician-rated, 7-point scale to assess how much the patient's illness (here: the patient's irritability) has changed relative to baseline. Scores range from 1 (very much improved) to 7 (very much worse).

    Time frame: 52 weeks

07

Results

Posted Dec 3, 2025
Limitations and caveats
The study was terminated early by the Sponsor due to lack of efficacy in the antecedent double-blind study (ACP-103-069).

Participant flow

This was an open-label extension study of the antecedent double-blind study ACP-103-069. Patients were eligible for this study if they had completed the treatment period of study ACP-103-069.

Participant flow — Overall Study
MilestonePimavanserin
Started209
Completed67
Not completed142
Withdrew: Adverse event7
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up10
Withdrew: Noncompliance with study drug5
Withdrew: Physician decision2
Withdrew: Study terminated by sponsor80
Withdrew: Prohibited medication use2
Withdrew: Withdrawal by subject20
Withdrew: Not further specified4

Outcome measures

PrimaryTreatment-emergent Adverse Events

Number (%) of patients with treatment emergent adverse events

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events
ParticipantsPimavanserin
Treatment-emergent Adverse Events132
SecondaryAberrant Behavior Checklist-Irritability (ABC-I) and Clinical Global Impression-Improvement (CGI-I) Response Rate

The response rate was defined as the proportion of patients with at least 25% reduction from baseline to Week 52 in ABC-I and a CGI-I of irritability score of 1 (very much improved) or 2 (much improved) at Week 52, compared to baseline. Baseline was the baseline of the antecedent double-blind study APC-103-069. The ABC is a parent/caregiver-rated scale comprised of 5 subscales encompassing 58 items. Subscales are irritability, lethargy, stereotypic behavior, hyperactivity, and inappropriate speech. Items are rated on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe), with higher scores indicating more severe problems. Subscale scores are calculated by summing the items within that subscale. The CGI-I is a clinician-rated, 7-point scale to assess how much the patient's illness (here: the patient's irritability) has changed relative to baseline. Scores range from 1 (very much improved) to 7 (very much worse).

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Aberrant Behavior Checklist-Irritability (ABC-I) and Clinical Global Impression-Improvement (CGI-I) Response Rate
ParticipantsPimavanserin
Aberrant Behavior Checklist-Irritability (ABC-I) and Clinical Global Impression-Improvement (CGI-I) Response Rate51

Adverse events

Collected over 52 weeks (study terminated early by the sponsor). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pimavanserin0/209 (0%)5/209 (2.4%)66/209 (31.6%)
Most frequent serious events
Most frequent serious events
EventPimavanserin
Drug hypersensitivityImmune system disorders1/209
Pneumonia respiratory syncytial viralInfections and infestations1/209
Heart rate irregularInvestigations1/209
Febrile convulsionNervous system disorders1/209
AggressionPsychiatric disorders1/209
Most frequent other events
Most frequent other events
EventPimavanserin
Upper respiratory tract infectionInfections and infestations21/209
VomitingGastrointestinal disorders15/209
HeadacheNervous system disorders14/209
NasopharyngitisInfections and infestations13/209
PyrexiaGeneral disorders11/209

Baseline characteristics

All patients enrolled and treated

Age, Continuous
Age, Continuous(years)Pimavanserin
Mean10.1 ± 3.16
Sex: Female, Male
Sex: Female, Male(Participants)Pimavanserin
Female46
Male163
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pimavanserin
American Indian or Alaska Native1
Asian9
Native Hawaiian or Other Pacific Islander1
Black or African American24
White158
More than one race0
Unknown or Not Reported16
Region of Enrollment
Region of Enrollment(participants)Pimavanserin
Hungary17
United States98
Poland55
Italy9
France11
Serbia9
Australia6
Spain4
08

Study locations

48 sites
  • Southwest Autism Research and Resource Center
    Phoenix, Arizona 85006, United States
  • Cortica Inc. (Glendale)
    Glendale, California 91361, United States
  • Cortica Inc.
    San Rafael, California 94903, United States
  • 1st Allergy and Clinical Research Group, d/b/a IMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Children's Research Institute
    Washington D.C., District of Columbia 20010, United States
  • The EHS Medical Practice, PA, D/B/A Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • APG Research, LLC
    Orlando, Florida 32803-3809, United States
  • AMR Baber Research Incorporated
    Naperville, Illinois 60563, United States
  • Clinical Research of Southern Nevada, LLC
    Las Vegas, Nevada 89128, United States
  • ERG Clinical Research - New York, PLLC DBA Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • Quest Therapeutics of Avon Lake dba Haidar Almhana Nieding LLC
    Avon Lake, Ohio 44012, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19146, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Relaro Medical Trials, LLC
    Dallas, Texas 75243, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • Eastside Therapeutic Resource, Inc. dba Core Clinical Research
    Everett, Washington 98201, United States
  • Children's Health Queensland Hospital and Health Service
    South Brisbane, Queensland 4101, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Murdoch Children's Research Institute
    Parkville, Victoria 3052, Australia
  • Centre Hospitalier Charles Perrens
    Bordeaux, 33076, France
  • Centre de Ressources Autisme Rhône-Alpes - Center Hospitalier le Vinatier
    Bron, 69678, France
  • CHU de Nantes
    Nantes, 44093, France
  • L'Assistance Publique - Hôpitaux de Paris, labélisé Institut Carnot
    Paris, 75019, France
  • Magyarországi Református Egyház Bethesda Gyermekkórháza
    Budapest, H-1146, Hungary
  • Békés Megyei Központi Kórház
    Gyula, H-5700, Hungary
  • Szegedi Tudományegyetem
    Szeged, H-6725, Hungary
  • La Nostra Famiglia - Scientifica IRCCS Eugenio Medea
    Bosisio Parini, LC 23842, Italy
  • Policlinico Riuniti - Azienda Ospedaliero Universitaria
    Foggia, 71122, Italy
  • Azienda Ospedaliera Universitaria "Federico II"
    Naples, 80131, Italy
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino - IRCCS
    Pavia, 27100, Italy
  • Fondazione PTV - Policlinico Tor Vergata
    Rome, 00133, Italy
  • Azienda Ospedaliera Universitaria Integrata di Verona (AOUI)
    Verona, 37126, Italy
  • Gdańskie Centrum Zdrowia Sp. z o.o.
    Gdansk, 80-542, Poland
  • Centrum Badań Klinicznych PI-House Sp. z o.o.
    Gdansk, 80-546, Poland
  • NAVICULA - Centrum Diagnozy i Terapii Autyzmu
    Lodz, 91-129, Poland
  • Ginemedica Sp. Zoo, S. K.
    Wroclaw, 50-414, Poland
  • Centrum Neuropsychiatrii Neuromed SP ZOZ
    Wroclaw, 54-238, Poland
  • MedicMental Indywidualna Specjalistyczna Praktyka Lekarska Monika Szewczuk-Boguslawska
    Wroclaw, 54-617, Poland
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • University Clinical Center Kragujevac, Clinic for Psychiatry
    Kragujevac, 34000, Serbia
  • University Clinical Center Nis, Center for Mental Health
    Niš, 18000, Serbia
  • Clinical Center of Vojvodina, Clinic for Psychiatry
    Novi Sad, 21000, Serbia
  • Hospital General de Alicante
    Alicante, 03010, Spain
  • Institut Global d´Atenció Integral del Neurodesenvolupament (IGAIN)
    Barcelona, 08007, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Feb 2025, 27 months.

Results were first posted in Dec 2025, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2022
First posted
Sep 27, 2022
StartActual
Nov 2, 2022
Primary completionActual
Feb 14, 2025
CompletionActual
Feb 14, 2025
Results first posted
Dec 3, 2025
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05555615
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Nov 2, 2022
Primary completion
Feb 14, 2025
Completion
Feb 14, 2025
Results posted
Dec 3, 2025
Last update
Dec 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimavanserin

Start the discussion